Aptargroup, Inc. ATR
The biggest changes in the 10-K filed Feb 6, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Cash from operations
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“The lower operating cash flow during 2025 was primarily a result of timing of payments on income taxes primarily in Germany, France and the US.”
Read it in the 10-K
Operating margin
Change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
Revenue
Change, FY to Dec 31, 2025 vs Dec 31, 2024
“Core sales to the consumer health care market declined 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products.”
Read it in the 10-K
“Core sales of our active material science solutions increased 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales due to a large tooling sale in the previous year period.”
Read it in the 10-K
Net income
Change, FY to Dec 31, 2025 vs Dec 31, 2024
The MD&A has no sentence that names a cause for this change.
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +5.4%
“Core sales to the consumer health care market declined 8% as higher demand for our eye care solutions was offset by lower sales of nasal decongestant, nasal saline and cough and cold products.”
Read it in the FY 2025 10-K“Core sales of our active material science solutions increased 3% as higher demand for our active film and diabetes treatment technologies more than compensated for lower tooling sales due to a large tooling sale in the previous year period.”
Read it in the FY 2025 10-K -
FY 2024 +2.7%
“Reported and core sales grew 3%, with annual sales of $3.6 billion, driven by favorable product mix and volume growth”
Read it in the FY 2024 10-K“Core sales to the consumer health care market declined 4% as higher demand for our eye care solutions was offset by lower sales of nasal saline and cough and cold products due to a soft 2023-2024 cold and flu season and customer inventory management.”
Read it in the FY 2024 10-K
Operating margin
0 of 2 years explained-
FY 2025 -0.6 pts
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +2.3 pts
The FY 2024 MD&A has no sentence that names a cause for this change.
Net income
0 of 2 years explained-
FY 2025 +4.9%
The FY 2025 MD&A has no sentence that names a cause for this change.
-
FY 2024 +31.7%
The FY 2024 MD&A has no sentence that names a cause for this change.
Cash from operations
2 of 2 years explained-
FY 2025 -11.4%
“The lower operating cash flow during 2025 was primarily a result of timing of payments on income taxes primarily in Germany, France and the US.”
Read it in the FY 2025 10-K -
FY 2024 +11.9%
“Cash flow from operations is primarily derived from improved net income generation year over year.”
Read it in the FY 2024 10-K
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ATR/export.csv") into a cell.